Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.
Related news for (BBIO)
- BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
- BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
- bridgebio pharma reports topline results from phase 1/2 trial of investigational gene therapy for congenital adrenal hyperplasia (cah)
- BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)